SIMULATION OF TARGETED TRANSPORT FOR DRUG SUBSTANCES PART 1: A SINGLE ADMINISTRATION
https://doi.org/10.21294/1814-4861-2017-16-1-59-65
Abstract
In oncology practice, despite advances in methods for early detection, surgery, radiotherapy, laser therapy, targeted therapy, etc., chemotherapy is unlikely to lose its relevance in the near future. In this context, the development of new antitumor drugs is one of the urgent problems of modern conservative oncology. Despite the importance of the search for new compounds with antitumor activity, the clinical potential of the «old» agents does not yet seem to be exhausted. The transport of antitumor agents can give them a «second life» in the clinic. When developing the targeted transport for chemotherapeutic drugs, the changes in their pharmacodynamics and pharmacokinetics are of great importance. A pharmacokinetic model of targeted transport of drug substances has been described in this paper. There have been described conditions under which it is worth to search for facility of transport for the initial active agent. Primary screening of antitumor agents have been undertaken to modify them for the targeted transport based on underlying assumptions of the model.
About the Authors
A. V. Zaborovskiy
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Russian Federation
MD, PhD, Associate Professor, Pharmacology Department
SPIN-code: 9592-2405
K. G. Gurevich
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Russian Federation
MD, DSc
SPIN-code: 4344-3045.
References
1. Ivonin А.G., Pimenov Е.V., Oborin V.А., Devrishov D.А., Kopylov S.N. Targeted drug transport: Current state and prospects. News of Komi Scientific Center of Ural Branch of Russian Academy of Science. 2012; 9: 46–55. [in Russian]
2. Berezov Т.Т., Yaglova N.V., Dmitrieva Т.B., Zhirkov Yu.А., Chekhonin V.P. The use of liposomes for drug delivery. Bulletin of the Russian Academy of Medical Science. 2004; 5: 42–47. [in Russian]
3. Sanzhakov М.А., Ignatov D.V., Kostryukova L.V., Druzhilovskaya О.S., Medvedeva N.V., Prozorovsky V.N., Ipatova О.М. Study of the properties of doxorubicin compositions composed of colloidal nanoparticles in experiments in vivo. Biomedical Chemistry. 2016; 62 (2): 150–153. [in Russian]
4. Yabbarov N.G., Posypanova G.А., Vorontsov Е.А., Popova О.N., Severin Е.S. Doxorubicin transport: delivery system based on pamam dendrimers. Biochemistry. 2013; 78 (8): 1128–1140. [in Russian]
5. Pyataev N.А., Gurevich К.G., Zaborovsky А.V., Kokorev А.V., Minaeva О.V., Zyrnyaeva N.А., Kladuev А.А., Bychkovskiy P.P., Revmtovich М.Yu. The effectiveness of a combination of free and polymer-bound forms of prospidin with doxorubicin in rats with Zajdela ascitic hepatoma. Chemical and Pharmaceutical Journal. 2014; 48 (11): 96–100. [in Russian]
6. Zyrnyaeva N.N., Minaeva О.V., Brodovskaya Е.P., Stolyarov G.S., Firstov S.А., Zaborovsky А.V., Shemstudinova Е.E. Comparative effectiveness of methods of targeted chemotherapy in experimental carcinoma рс-1 in rats. Current problems of science and education. 2015; 6 0: 76. [in Russian]
7. Gorbik P.P., Petranovskaya А.L., Turelik М.P., Abramov N.V., Turanskaya S.P., Pilipchuk Е.V., Chekhun V.F. Problem of targeted drug transport: current state and prospects. Chemistry, Physic and Superficial Technologies. 2011; 2 (4): 461–469. [in Russian]
8. Pyataev N.А., Gurevich К.G., Skopin P.I., Minaeva О.V. Targeted pharmacotherapy in oncology. Medicine of critical conditions. 2010; 5: 3–14. [in Russian]
9. Gervas P.A., Litviakov N.V., Popova N.O., Dobrodeev A.Yu., Tarasova A.S., Yumov E.L., Ivanova F.G., Cheremisina O.V., Afanasyev S.G., Goldberg V.E., Cherdyntseva N.V. Problem and perspective to improve molecular testing to choose appropriate target therapy. Siberian Journal of Oncology. 2014; 2: 46–55. [in Russian]
10. Ulashchik V.S. Current technologies of the targeted drug transport. Health care (Minsk). 2015; 4: 12–19. [in Russian]
11. Zaborovskiy А.V., Tararina L.А., Mulyar АG., Pyataev N.А., Gurevich К.G. Development of novel anticancer agents on the basis of polymer nanoparticles for cancer treatment. The system analysis and management in biomedical systems. 2016; 15 (3): 401–403. [in Russian]
12. Pyataev N.А., Gurevich К.G., Belyaev А.N., Minaeva О.V. Pharmacokinetics and pharmacodynamics of antibacterial agents for targeted transport in patients with severe pneumonia. Medicine of critical conditions. 2008; 3 (3): 11–17. [in Russian]
13. Gurevich К.G., Romanov М.D., Belyaev А.N., Pyataev N.А., Minaeva О.V. Comparative pharmacokinetics of erythromycin in the target cell-associated transport and intravenous administration in patients with pneumonia. Bulletin of Moscow State University. 2006; 2: 109–114. [in Russian]
14. Varfolomeev S.D., Gurevich К.G. Biokinetics. Practical course. Moscow, 1999; 720 p. [in Russian]
15. Pérez-Blanco J.S., Santos-Buelga D., Fernández de Gatta M.D., Hernández-Rivas J.M., Martín A., García M.J. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with nonHodgkin’s lymphoma. Br J Clin Pharmacol. 2016 Dec; 82 (6): 1517–1527. doi: 10.1111/bcp.13070.
16. Gong C., Qian L., Yang H., Ji L.L., Wei H., Zhou W.B., Qi C., Wang C.H. Hepatotoxicity and pharmacokinetics of cisplatin in combination therapy with a traditional Chinese medicine compound of Zengmian Yiliu granules in ICR mice and SKOV-3-bearing nude mice. BMC Complement Altern Med. 2015 Aug 18; 15: 283. doi: 10.1186/ s12906-015-0799-9.
17. Li J., Chen R., Ji M., Zou S.L., Zhu L.N. Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis. Cancer Chemother Pharmacol. 2015 Sep; 76 (3): 651–5. doi: 10.1007/s00280-015-2804
18. Balis F.M., Holcenberg J.S., Bleyer W.A. Clin Pharmacokinet. 1983 May-Jun; 8 (3): 202–32.
19. Balis F.M., Holcenberg J.S., Bleyer W.A. Clinical pharmacokinetics of commonly used anticancer drugs. Clinical pharmacokinetics. 1983; 8 (3): 202–232.
20. Canal P., Chatelut E., Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs. 1998 Dec; 56 (6): 1019–38.
21. Crombag M.R., Joerger M., Thürlimann B., Schellens J.H., Beijnen J.H., Huitema A.D. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers (Basel). 2016 Jan 2; 8 (1). pii: E6. doi: 10.3390/cancers8010006.
22. Kerr D.J., Haller D.G., C.J.H. van de Velde, Baumann M. Oxfrord textbook of oncology. Oxford: OUP, 2016; 975 p. [in Russian]
23. Korman D.B. Targets and mechanisms of action of anticancer drugs. М.: Practical Medicine. 2014; 336 p. [in Russian]
24. Liang C., Xu L., Song G., Liu Z. Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototerapy, andimmunoterapy. Chem Soc Rev. 2016 Nov 7; 45 (22): 6250–6269.
25. Moskalyeva Е.Yu., Semochkina Yu.P., Rodina А.V., Severin S.Е. Somatostatin analogues as vector molecules to create a targeted anticancer drugs. Molecular Medicine. 2014; 1: 3–12. [in Russian]
26. Gelperina S.E., Smirnova Z.S., Skidan I.N., Kroiter I. Study of nanosomal form of doxorubicin. Russian Biotherapeutic Journal. 2004; 3(3): 56 64. [in Russian]
Review
For citations:
Zaborovskiy A.V., Gurevich K.G. SIMULATION OF TARGETED TRANSPORT FOR DRUG SUBSTANCES PART 1: A SINGLE ADMINISTRATION. Siberian journal of oncology. 2017;16(1):59-65. (In Russ.) https://doi.org/10.21294/1814-4861-2017-16-1-59-65
Views:
992
Email this article 
